Literature DB >> 7297024

Disposition of intravenous radioactive acyclovir.

P de Miranda, S S Good, O L Laskin, H C Krasny, J D Connor, P S Lietman.   

Abstract

The kinetic and metabolic disposition of (8-14C)acyclovir (ACV) was investigated in five subjects with advanced malignancy. The drug was administered by 1-hr intravenous infusion at doses of 0.5 and 2.5 mg/kg. Plasma and blood radioactivity-time, and plasma concentration-time data were defined by a two-compartment open kinetic model. There was nearly equivalent distribution of radioactivity in blood and plasma. The overall mean plasma half-life and total body clearance +/- SD of ACV were 2.1 +/- 0.5 hr and 297 +/- 53 ml/min/1.73 m2. Binding of ACV to plasma proteins was 15.4 +/- 4.4%. Most of the radioactive dose excreted was recovered in the urine (71% to 99%) with less than 2% excretion in the feces and only trace amounts in the expired Co2. Analyses by reverse-phase high-performance liquid chromatography indicated that 9-(carboxymethoxymethyl)guanine was the only significant urinary metabolite of ACV, accounting for 8.5% to 14.1% of the dose. A minor metabolite (less than 0.2% of dose) had the retention time of 8-hydroxy-9-[(2-hydroxyethoxy)methyl]guanine. Unchanged urinary ACV ranged from 62% to 91% of the dose. There was no indication of ACV cleavage to guanine. Renal clearance of ACV was approximately three times the corresponding creatinine clearances.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7297024     DOI: 10.1038/clpt.1981.218

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  Nobel lecture in physiology or medicine--1988. The purine path to chemotherapy.

Authors:  G B Elion
Journal:  In Vitro Cell Dev Biol       Date:  1989-04

Review 2.  Saturable pharmacokinetics in the renal excretion of drugs.

Authors:  C A van Ginneken; F G Russel
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

3.  The Interesting Case of Acyclovir Delivered Using Chitosan in Humans: Is it a Drug Issue or Formulation Issue?

Authors:  Nuggehally R Srinivas
Journal:  Pharm Res       Date:  2015-10-16       Impact factor: 4.200

4.  Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir.

Authors:  Xiaomei I Liu; Jeremiah D Momper; Natella Rakhmanina; John N van den Anker; Dionna J Green; Gilbert J Burckart; Brookie M Best; Mark Mirochnick; Edmund V Capparelli; André Dallmann
Journal:  J Clin Pharmacol       Date:  2019-09-06       Impact factor: 3.126

Review 5.  Pharmacokinetics of new antiherpetic agents.

Authors:  P Rolan
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of acyclovir.

Authors:  O L Laskin
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

Review 7.  A personalized medicine approach for Asian Americans with the aldehyde dehydrogenase 2*2 variant.

Authors:  Eric R Gross; Vanessa O Zambelli; Bryce A Small; Julio C B Ferreira; Che-Hong Chen; Daria Mochly-Rosen
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-09-29       Impact factor: 13.820

8.  Pharmacokinetics and tolerance of desciclovir, a prodrug of acyclovir, in healthy human volunteers.

Authors:  B G Petty; R J Whitley; S Liao; H C Krasny; L E Rocco; L G Davis; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

9.  Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection.

Authors:  T A Tartaglione; A C Collier; K Opheim; F G Gianola; J Benedetti; L Corey
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 10.  Comparative pharmacokinetics of antiviral nucleoside analogues.

Authors:  G D Morse; M J Shelton; A M O'Donnell
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.